We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies.
Present your Company
The DESERT ANGELS ™ welcomes applications from startup or early stage companies. We evaluate applications on an ongoing basis and meet monthly from September through June.
Present your company
Become a member
As a vibrant, growing organization, the DESERT ANGELS ™ welcomes new members. If you are an accredited investor with a tenacious appetite for helping early-stage companies succeed, we’d love to get to know you better at an upcoming dinner meeting.
It is safe to say that there would have been no Calimmune without the early support of the Desert Angels.
Many members of the DA share our passion and see the potential for gene therapy to transform healthcare and liberate patients from chronic and incurable diseases. Their investments have helped us grow this company to what it is today. We truly hope Calimmune’s work will be life-changing for the people we plan to serve and the investors that supported us.
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer therapeutics, today announced that Jeff Behrens, president and chief executive officer, will present at the 10thannual Biotech Showcase™ conference in San Francisco on Tuesday, January 9, 2018 at 1:45 p.m. PT. The conference will be held January 8-10, 2018, at the Hilton San Francisco Union Square. […]
NuvOx Pharma, a clinical stage biotechnology company based in Tucson, Arizona, has received a Phase I SBIR grant for $150,000 from the National Institutes of Health, specifically the National Institute of Neurological Diseases and Stroke (NINDS). This grant will fund development of a novel syringe sonication device that may allow quick preparation of an investigational […]
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications today announced a new Master Collaboration Agreement for translational programs with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The Master Collaboration Agreement complements the previously announced Master Companion Diagnostic Agreement with Merck KGaA, Darmstadt, Germany and […]